Pannus

Pannus, medically known as chronic superficial keratitis, is an immune-mediated inflammatory disease affecting the cornea of dogs that, without treatment, progressively leads to vision impairment and potential blindness. This condition occurs when the immune system inappropriately targets corneal tissue, causing inflammation, blood vessel growth, pigmentation, and scarring that gradually obscures the normally transparent cornea. Pannus is particularly common in certain breeds, with German Shepherds showing such high prevalence that the condition has historically been called German Shepherd pannus. While not curable, pannus is highly manageable with appropriate lifelong treatment, and affected dogs can maintain good vision and quality of life with proper care.

The underlying cause of pannus involves a complex interaction between genetic predisposition, immune dysregulation, and environmental triggers, particularly ultraviolet light exposure. In affected dogs, immune cells infiltrate the cornea, initiating an inflammatory cascade that damages corneal tissue and stimulates compensatory responses including blood vessel growth and pigment deposition. The disease typically begins at the lateral or temporal aspect of the cornea, near the junction with the white of the eye, and progressively extends centrally toward the visual axis. The characteristic appearance includes a vascularized, pigmented, granular tissue that advances across the corneal surface. A related condition called plasmacytic conjunctivitis often accompanies pannus and affects the third eyelid.

The impact of pannus on affected dogs depends heavily on the stage at which treatment is initiated and the consistency of ongoing therapy. In early stages, dogs may show minimal clinical signs, with changes detectable only on close examination. As the disease progresses without treatment, corneal opacity increases, causing visual impairment that worsens over time. Advanced untreated cases can result in complete corneal coverage with opaque, vascularized tissue and functional blindness. The condition affects both eyes, though often asymmetrically. Dogs experience no significant pain from pannus itself, which can paradoxically lead to delayed diagnosis as owners may not notice the gradual changes until substantial vision loss has occurred.

Pannus requires lifelong management rather than cure, but the prognosis for maintaining functional vision is good with consistent treatment. Topical immunosuppressive medications suppress the immune attack on corneal tissue, halting progression and often producing partial regression of existing changes. Treatment must continue indefinitely, as discontinuation allows disease progression to resume. Environmental management, particularly reducing ultraviolet light exposure, complements medical therapy. Regular veterinary monitoring ensures treatment remains effective and allows adjustment of medication regimens as needed. The key message for owners of affected dogs is that commitment to lifelong treatment is essential but rewarding, as it preserves vision and quality of life.

The primary cause of pannus is immune dysregulation in which the body's own immune system mounts an inflammatory attack against corneal tissue. This autoimmune process involves T-lymphocytes and plasma cells infiltrating the cornea, releasing inflammatory mediators that damage tissue and trigger characteristic changes. The immune cells target corneal cells and extracellular matrix components, initiating cascades of inflammation and tissue remodeling. Why the immune system attacks the cornea in susceptible dogs is not fully understood, but the process shares features with other autoimmune diseases. The cornea's unique immunological properties, being normally transparent and avascular, may become dysregulated in ways that trigger immune recognition.

Genetic factors play a dominant role in pannus development, with certain breeds showing overwhelming predisposition. German Shepherds have the highest prevalence, with some studies suggesting up to thirty percent of the breed may be affected to some degree. Belgian Shepherds, including Belgian Malinois, Belgian Tervuren, and Belgian Sheepdog varieties, show similar high rates. Greyhounds demonstrate significant susceptibility, particularly those with racing backgrounds. Border Collies, Siberian Huskies, and Australian Shepherds appear in case series at rates above the general population. The consistent breed associations indicate heritable components to disease susceptibility, though the specific genetic mechanisms have not been completely characterized. Dogs with affected parents or siblings face elevated risk.

Environmental factors, particularly ultraviolet light exposure, significantly influence pannus severity and progression. The strong correlation between UV exposure and disease activity has been demonstrated through geographic studies showing higher prevalence and severity at high altitudes where UV radiation is more intense. Dogs living in sunny climates or those spending significant time outdoors during peak UV hours experience more aggressive disease. Seasonal variation in disease activity, with worsening during summer months, further supports the UV connection. The mechanism involves UV-induced damage to corneal cells and extracellular matrix, enhancing immune recognition and inflammatory responses. This environmental component provides opportunities for disease management through UV exposure reduction.

Risk factors beyond genetics and UV exposure include age, geographic location, and potentially other environmental elements. Pannus typically develops in young adult to middle-aged dogs, with most cases diagnosed between three and seven years of age, though earlier or later onset can occur. Living at high altitude increases risk regardless of breed, and relocating to lower elevations can improve disease control. Dry, dusty environments may contribute to corneal surface stress that exacerbates immune-mediated damage. Some evidence suggests that certain infections or inflammatory triggers may initiate disease in genetically susceptible individuals, though this remains speculative. Prior ocular surface disease or trauma has not been established as a risk factor.

The mechanism of pannus development involves a sequence of inflammatory changes that progressively obscure the cornea. The disease begins with accumulation of lymphocytes and plasma cells in the limbal area, the junction between cornea and sclera. These immune cells migrate onto the corneal surface, creating a visible area of infiltration. Blood vessels follow, growing from the limbus into the normally avascular cornea in a process called neovascularization. Pigment-producing cells migrate along these blood vessels, depositing melanin in the corneal tissue. Simultaneously, granulation tissue forms and fibrosis develops, replacing normal transparent corneal structure with opaque scar tissue. The lateral or temporal cornea is affected first in most cases, with progression occurring centrally and eventually affecting the visual axis if untreated.

The early warning signs of pannus are often subtle and may be missed by owners, making routine veterinary eye examinations valuable for early detection in predisposed breeds. The earliest changes typically appear as a subtle reddish-brown discoloration or slight cloudiness at the lateral edge of one or both corneas. Fine blood vessels may be visible growing onto the clear cornea from the white of the eye. A slight change in the eye's reflective quality may be noticeable. Dogs show no obvious signs of discomfort or pain at this stage, as pannus is not typically painful. Vision remains normal because the central cornea is not yet affected. These early changes are most visible under good lighting and may require close examination to detect.

As pannus progresses, the corneal changes become more obvious and concerning to observant owners. The vascularized, pigmented tissue expands centrally from its starting point at the corneal edge. The affected area develops a characteristic granular, rough appearance distinctly different from normal corneal smoothness. Pigmentation intensifies, with brown or black melanin deposits becoming visible. The cornea takes on an increasingly opaque appearance in the affected areas. Blood vessel growth becomes more prominent, with vessels clearly visible extending across the corneal surface. Both eyes are typically affected, though often asymmetrically, with one eye showing more advanced changes than the other.

Behavioral changes associated with pannus relate primarily to visual impairment as the disease progresses. In early stages, behavior remains normal as vision is not affected. As opacity extends toward the central visual axis, dogs may show subtle signs of visual difficulty, particularly in dim lighting or unfamiliar environments. Dogs may startle more easily or appear uncertain when navigating new spaces. Ball catching or toy tracking may become less accurate. Some dogs develop increased reliance on other senses, appearing to sniff more when exploring. Advanced cases with significant central corneal involvement may show obvious visual impairment including bumping into objects and difficulty finding dropped items. The gradual progression allows dogs to adapt, potentially masking the extent of vision loss.

Physical examination reveals the characteristic findings that define pannus and distinguish it from other corneal conditions. The classic appearance includes a vascularized, pigmented, granular tissue advancing across the cornea from the lateral limbus. The leading edge shows active inflammation with prominent vessels, while older affected areas show denser pigmentation and scarring. Superficial corneal vessels, as opposed to deep vessels, characterize the condition. Corneal edema may be present at the advancing edge. Examination of the third eyelid often reveals associated plasmacytic conjunctivitis, appearing as thickened, depigmented tissue. The eyes are typically comfortable with no significant blepharospasm or discharge. Both eyes should be evaluated, as bilateral disease is the norm.

Symptom progression in untreated pannus follows a predictable pattern of gradual visual deterioration. The vascularized, pigmented tissue continues advancing centrally over months to years. Eventually, the visual axis becomes affected, causing noticeable vision problems. The entire cornea may become covered in advanced cases, resulting in functional blindness. The rate of progression varies between individuals and is influenced by UV exposure, breed, and potentially other factors. Some dogs show relatively stable disease while others progress more rapidly. Seasonal worsening during summer months is common. Without treatment, the progression is relentless, though typically slow enough that dogs adapt somewhat to their diminishing vision.

Pannus itself does not typically produce emergency symptoms, as it is a chronic, progressive condition rather than an acute illness. However, several related situations warrant prompt veterinary attention. Sudden worsening or change in appearance could indicate concurrent ulceration or infection. Development of significant discomfort with squinting and tearing suggests a complicating condition. Rapid vision deterioration beyond the expected progression rate needs evaluation. Any acute eye problem in a dog with pannus requires veterinary assessment to determine whether it relates to the underlying condition or represents a new problem. Regular monitoring allows early detection of disease progression or complications, even though true emergencies are uncommon.

The diagnostic process for pannus typically begins when characteristic corneal changes are noted during routine examination or when owners bring their dog for evaluation of visible eye changes. The veterinarian will obtain a thorough history, including breed, age, living environment, outdoor habits, and any previous eye problems. The classic signalment of a German Shepherd or related breed presenting with bilateral corneal vascularization and pigmentation strongly suggests pannus. Both eyes should be carefully examined, as bilateral involvement is expected and helps confirm the diagnosis. Basic vision assessment provides a baseline for monitoring disease progression and treatment response.

Ophthalmic examination reveals the characteristic findings that allow diagnosis based on clinical appearance. The pathognomonic presentation includes superficial corneal vascularization, pigmentation, and granulation tissue originating at the lateral limbus and extending centrally. Examination with magnification allows detailed assessment of vessel depth, confirming the superficial location characteristic of pannus. The third eyelid should be everted to check for plasmacytic conjunctivitis, which appears as thickened, rough, depigmented tissue and accompanies pannus in many cases. Fluorescein staining is performed to detect any concurrent corneal ulceration, which would require additional treatment. Schirmer tear testing rules out concurrent dry eye that could complicate management.

Differential diagnosis includes other conditions that cause corneal vascularization and pigmentation. Pigmentary keratitis, common in brachycephalic breeds, causes pigment deposition without the typical pannus pattern and responds differently to treatment. Chronic corneal ulceration can stimulate vascularization but typically shows fluorescein uptake and ulcer characteristics. Corneal scarring from previous trauma or disease may cause localized opacity. Corneal degenerations and dystrophies can produce corneal opacity through different mechanisms. Anterior uveitis can cause secondary corneal changes. The characteristic appearance, breed predisposition, and bilateral presentation usually make pannus diagnosis straightforward, but atypical cases may require careful differentiation.

In most cases, pannus is diagnosed based on clinical appearance without requiring additional testing. However, certain situations warrant further evaluation. Cytology from corneal samples, if obtained during surgical procedures, shows characteristic lymphocytic and plasmacytic infiltration. Biopsy can provide definitive histopathological confirmation but is rarely necessary for diagnosis. If concurrent conditions such as keratoconjunctivitis sicca are suspected, appropriate testing should be performed. Young dogs or breeds not typically associated with pannus presenting with suggestive changes may warrant more thorough evaluation to rule out other conditions. Response to treatment serves as a form of therapeutic diagnosis, as rapid improvement with immunosuppressive therapy supports the diagnosis.

The foundation of pannus treatment is topical immunosuppressive therapy, which must continue lifelong to maintain disease control. Topical corticosteroids such as prednisolone acetate or dexamethasone have historically been the mainstay of treatment, suppressing local immune activity and reducing inflammation. These medications are highly effective but carry risks of side effects with long-term use, including potential for corneal ulceration and local immunosuppression. Newer topical immunomodulators, particularly cyclosporine and tacrolimus, have largely replaced or supplemented corticosteroids for long-term management. These medications work by specifically suppressing T-lymphocyte activation, addressing the underlying immune dysregulation with fewer side effects than corticosteroids.

Medical management protocols typically start with intensive therapy to gain control of active disease, followed by reduction to maintenance dosing. During the initial intensive phase, medications may be applied two to four times daily to suppress active inflammation and begin reversing corneal changes. As improvement occurs over weeks to months, the frequency can often be reduced to once or twice daily maintenance therapy. Many dogs achieve good long-term control with once-daily application of cyclosporine or tacrolimus, sometimes combined with intermittent corticosteroid use during flare-ups. The specific protocol is tailored to individual response, with veterinary guidance essential for safe and effective management.

Environmental management complements medical therapy by reducing the UV exposure that drives disease activity. UV-blocking dog goggles, commercially available as products like Rex Specs or Doggles, provide direct protection during outdoor activities. Limiting outdoor time during peak UV hours, typically between ten in the morning and four in the afternoon, reduces exposure. Providing shaded rest areas for outdoor dogs minimizes UV contact. For severely affected dogs or those living at high altitude, geographic relocation to lower, less sunny areas can improve disease control, though this drastic measure is rarely necessary with modern medical management.

Surgical intervention may be considered for specific indications but is not standard treatment for uncomplicated pannus. Superficial keratectomy can remove dense corneal pigmentation and scarring that obscures vision, potentially improving visual function in advanced cases. However, without ongoing medical management, disease recurrence and progression will occur after surgery. Beta radiation therapy has been used in refractory cases to suppress local immune activity but is not widely available. Cryotherapy to affected areas has been attempted with variable success. In general, consistent medical management is more effective than surgical approaches for long-term disease control.

Supportive care measures enhance treatment success and patient quality of life. Regular recheck examinations, typically every three to six months once disease is controlled, allow monitoring for progression or complications. Owners should learn to assess their dog's eyes for changes that might indicate worsening. Tear film support with lubricating drops may benefit some dogs, particularly if concurrent dry eye is present. Maintaining overall health through appropriate nutrition and exercise supports immune function and general wellbeing. Consistency with medication administration is essential, as missed doses allow disease activity to increase.

Treatment decisions involve balancing disease control with practical considerations of cost, compliance, and side effects. Generic cyclosporine preparations offer cost-effective options for long-term management. Combination protocols using different medication classes may achieve better control in refractory cases. Side effects of topical medications are generally mild but can include local irritation or, with corticosteroids, increased susceptibility to corneal infection. The commitment to lifelong treatment requires owner dedication and reliable access to medications and veterinary care. For most affected dogs, the investment in consistent treatment is rewarded with preserved vision and normal quality of life.

The concept of recovery in pannus differs from typical disease resolution because this condition requires ongoing management rather than cure. Initial response to treatment typically shows visible improvement within two to four weeks, with reduced redness and inflammation at the leading edge of corneal involvement. Over several months of consistent treatment, vascularization diminishes as vessels regress, and pigmentation may partially fade. The degree of reversal depends on how advanced the disease was at treatment initiation, with early cases showing more dramatic improvement than those with established scarring. Complete return to normal corneal appearance is uncommon, but significant improvement is typical with appropriate therapy.

Post-diagnosis care involves establishing effective medication protocols and monitoring routines that will continue indefinitely. The initial intensive treatment phase may require multiple daily applications, gradually reducing as control is achieved. Finding the minimum effective maintenance regimen minimizes cost and burden while maintaining disease control. Regular veterinary examinations, typically every three to six months during stable periods, assess disease status and allow treatment adjustment. Owners become partners in monitoring, learning to recognize changes that might indicate increased disease activity. The transition from intensive treatment to maintenance represents successful initial management rather than treatment completion.

Prognosis for vision preservation is generally good with consistent treatment, particularly when diagnosis occurs before extensive central corneal involvement. Dogs diagnosed and treated early, while changes remain peripheral, typically maintain excellent functional vision throughout life. Those with more advanced disease at diagnosis may retain some degree of corneal opacity even with treatment but usually maintain useful vision. The prognosis worsens if treatment is delayed until dense central scarring has developed. Compliance with lifelong treatment is the most important prognostic factor, as even well-controlled disease will progress if medications are discontinued.

Long-term outlook for dogs with pannus involves acceptance of chronic disease requiring ongoing management. Most affected dogs live normal lifespans with good quality of life, their vision preserved through consistent treatment. Medication costs and veterinary monitoring visits become routine aspects of ownership. Disease may fluctuate, with periods of increased activity requiring treatment intensification. Seasonal worsening during summer months is common and may require temporary medication increases. The relationship between owner, dog, and veterinary team becomes important for optimal long-term outcomes. With appropriate management, pannus becomes a manageable chronic condition rather than a progressive cause of blindness.

Primary prevention of pannus is not currently possible because the condition results from genetic predisposition combined with environmental triggers rather than preventable causes. However, reducing UV light exposure may delay onset or reduce severity in genetically predisposed dogs. Owners of German Shepherds, Belgian Shepherds, Greyhounds, and other at-risk breeds can take proactive steps to minimize UV exposure from an early age. Limiting outdoor time during peak UV hours, providing shaded outdoor areas, and considering UV-blocking eyewear for dogs with significant outdoor exposure represent reasonable precautions. Whether these measures truly prevent pannus development or simply delay it is not established, but they carry no risk and may provide benefit.

Breeding considerations may eventually reduce pannus prevalence in affected breeds. Dogs diagnosed with pannus ideally should not be bred, though the late age of onset in some cases means dogs may produce offspring before diagnosis. Genetic testing, if developed for pannus susceptibility genes, could allow informed breeding decisions. Breed clubs can promote awareness of pannus prevalence and encourage health screening of breeding stock. Currently, no genetic tests specifically identify pannus susceptibility, limiting preventive breeding strategies. The complex genetics of the condition, likely involving multiple genes, makes development of such tests challenging.

Nutritional support and general health maintenance contribute to overall immune function but have not been specifically proven to prevent or modify pannus. Antioxidant-rich diets may support eye health at the cellular level. Omega-3 fatty acids have anti-inflammatory properties that theoretically could benefit immune-mediated conditions. Maintaining appropriate body weight supports overall health. Managing other health conditions optimally reduces general immune stress. While no specific dietary intervention prevents pannus, overall good nutrition supports the dog's ability to maintain health.

Early detection through regular veterinary screening offers the best strategy for at-risk breeds. German Shepherds, Belgian Shepherds, Greyhounds, and other predisposed breeds should receive thorough eye examinations at routine wellness visits. Annual ophthalmologic evaluation from young adulthood allows detection of early changes before vision is threatened. Owners of at-risk breeds should learn what early pannus looks like so they can recognize subtle changes at home. Establishing baseline eye examinations while dogs are young provides comparison for detecting early changes. Early treatment institution, before significant central corneal involvement, offers the best chance for long-term vision preservation.

Once pannus is diagnosed, preventing progression to vision loss becomes the management goal. Consistent treatment with appropriate immunosuppressive medications is essential. Environmental modifications to reduce UV exposure complement medical therapy. Regular monitoring allows early detection of increased disease activity requiring treatment adjustment. Owner education about the importance of lifelong treatment compliance prevents the gradual progression that occurs when medications are discontinued. The message for owners of affected dogs is that pannus is manageable, not curable, and commitment to ongoing care preserves vision.

Daily management of dogs with pannus centers on consistent medication administration and environmental awareness. Eye drops or ointments must be administered reliably on the prescribed schedule, typically once or twice daily for maintenance therapy. Establishing a routine, perhaps linked to feeding times or other daily activities, helps ensure doses are not missed. Medication should be stored properly and supplies reordered before running out. Owners should master proper technique for eye drop administration to ensure medication reaches the corneal surface effectively. Daily visual inspection of the eyes allows early detection of changes that might indicate increased disease activity.

Home environment modifications support disease management and overall quality of life. Indoor lighting should be comfortable, avoiding excessively bright conditions that might cause discomfort in dogs with significant corneal changes. Outdoor areas should include shaded options so dogs can escape direct sun exposure. Window films that block UV light can reduce indoor UV exposure in sunny climates. For dogs with significant visual impairment, maintaining consistent furniture arrangement and clear pathways prevents accidents. Water and food bowls should remain in predictable locations. These modifications become routine aspects of managing life with an affected dog.

Quality of life for dogs with pannus under good treatment control is typically excellent. Most affected dogs experience no pain from the condition and maintain normal vision with appropriate treatment. Activities can continue without significant restriction, though avoiding peak UV exposure hours is advisable. UV-blocking dog goggles allow outdoor activities during sunny periods with reduced risk of disease exacerbation. Dogs adapt readily to wearing protective eyewear with positive reinforcement training. Mental stimulation, social interaction, and physical exercise should continue normally. The focus should be on enjoying life with minor accommodations rather than viewing the dog as limited by disease.

Ongoing monitoring ensures treatment remains effective and allows response to changing disease activity. Owners should examine their dog's eyes daily, noting any changes in appearance that might indicate progression or flare-up. Increased redness, apparent spreading of corneal changes, or development of any new symptoms should prompt veterinary evaluation. Scheduled recheck appointments, typically every three to six months during stable periods, provide professional assessment of disease status. Photography of the eyes at consistent intervals helps track subtle changes over time. Open communication with the veterinary team allows timely treatment adjustments.

Caregiver considerations for owners of dogs with pannus include managing the emotional and practical aspects of chronic disease. The initial diagnosis can be concerning, but understanding that most dogs do well with treatment provides reassurance. The commitment to lifelong medication carries costs and requires consistency, factors owners should consider realistically. Connecting with others who have dogs with pannus, through online communities or breed clubs, provides support and practical advice. Veterinary teams can address concerns and optimize management for individual circumstances. Accepting pannus as a manageable condition rather than a catastrophe maintains perspective and allows focus on the dog's ongoing quality of life.

German Shepherds have by far the highest prevalence of pannus among all dog breeds, with estimates suggesting twenty to thirty percent of the breed may be affected to some degree. This overwhelming breed association has led to the historical term German Shepherd pannus, though the condition occurs in other breeds as well. The prevalence is high enough that German Shepherd owners should consider pannus screening part of routine health maintenance. German Shepherd breeding programs should consider eye health as a selection criterion, though the genetic complexity of the condition makes complete elimination through breeding challenging.

Other herding and working breeds show significant pannus prevalence. Belgian Shepherds, including Belgian Malinois, Belgian Tervuren, and Belgian Sheepdog varieties, have prevalence rates approaching those seen in German Shepherds. The close genetic relationship between Belgian and German Shepherds likely explains the shared susceptibility. Border Collies appear in case series at rates above the general population. Siberian Huskies and Australian Shepherds show some increased risk. The concentration of pannus in herding and working breeds suggests shared genetic factors within this broad group. Owners of these breeds should be aware of the condition and alert for early signs.

Greyhounds demonstrate notable pannus susceptibility, particularly those with racing backgrounds. The combination of genetic predisposition and the high UV exposure associated with track activities may contribute to disease in this population. Retired racing Greyhounds adopted as pets may present with established disease or develop it after adoption. The Greyhound predisposition reminds owners that pannus is not exclusively a herding breed disease. Greyhound adoption groups should inform adopters about pannus risk and the importance of eye health monitoring.

Screening recommendations for at-risk breeds emphasize regular eye examination from young adulthood. German Shepherds, Belgian Shepherds, and Greyhounds should have annual eye examinations starting at one to two years of age. Owners should request specific evaluation for pannus during these examinations. Early detection allows treatment institution before significant vision impairment. Breed clubs can promote awareness through health education programs. Prospective puppy buyers can request information about eye health in parent dogs, though the late onset of some cases means unaffected parents can produce affected offspring. The goal is catching disease early and managing it effectively, since current knowledge does not allow true prevention.

Pannus frequently occurs in association with plasmacytic conjunctivitis, an immune-mediated inflammation of the third eyelid that shares underlying mechanisms with corneal disease. This condition, sometimes called atypical pannus or third eyelid pannus, causes thickening, depigmentation, and roughening of the third eyelid margins. The two conditions often occur together in the same patient and respond to similar immunosuppressive treatment. When evaluating a dog for pannus, the third eyelid should always be examined for evidence of concurrent plasmacytic conjunctivitis. Treatment protocols typically address both conditions simultaneously.

Several conditions may resemble pannus and require differentiation for appropriate treatment. Pigmentary keratitis, common in brachycephalic breeds, causes corneal pigmentation without the vascularized, granulation tissue characteristic of pannus and responds differently to treatment. Chronic corneal ulceration can stimulate vascularization but shows different patterns and requires different management. Corneal scarring from previous disease or trauma may cause localized opacity. Lipid keratopathy and corneal dystrophies produce corneal opacity through different mechanisms. Accurate diagnosis ensures appropriate treatment selection and realistic prognostic expectations.

Complications of pannus include conditions that may develop as consequences of the disease or its treatment. Progressive vision loss occurs if treatment is inadequate or discontinued, with eventual blindness possible in advanced cases. Corneal scarring, while part of the disease process itself, represents permanent damage that limits visual recovery even with treatment. Long-term topical corticosteroid use can predispose to corneal infections, particularly if ulceration develops. Secondary dry eye can occur in some cases. Understanding these potential complications helps owners appreciate the importance of consistent treatment and regular monitoring while maintaining realistic expectations about outcomes.